Basic Stats
| LEI | 529900NDDXEAPTUTXP41 |
| CIK | 1023549 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to XTL Biopharmaceuticals Ltd. - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July, 2025 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 26 Ben-Gurion St. Ramat Gan, 5112001, Israel (Address of principal executiv |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July, 2025 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 26 Ben-Gurion St. Ramat Gan, Israel, 5257346 (Address of principal executiv |
|
| June 18, 2025 |
Exhibit 99.2 XTL Biopharmaceuticals Ltd. PROXY FOR THE ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 21, 2025 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Mr. Noam Band, Chief Executive Officer, attorneys, agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to vote on |
|
| June 18, 2025 |
NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 21, 2025 Exhibit 99.1 NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 21, 2025 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Annual and Extraordinary General Meeting (the “Meeting”) of the shareholders of XTL Biopharmaceuticals Ltd. (the “Company”) will be held at the offices of the Company’s attorneys, Doron Tikotzky Kantor Gutman |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2025 001-36000 (Commission File Number) XTL Biopharmaceuticals Ltd. (Exact name of Registrant as specified in its charter) 26 Ben-Gurion St. Ramat Gan, Israel, 5257346 (Address of princi |
|
| June 13, 2025 |
Exhibit 99.2 XTL Biopharmaceuticals Ltd. PROXY FOR THE ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 21, 2025 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Mr. Noam Band, Chief Executive Officer, attorneys, agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to vote on |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2025 001-36000 (Commission File Number) XTL Biopharmaceuticals Ltd. (Exact name of Registrant as specified in its charter) 26 Ben-Gurion St. Ramat Gan, Israel, 5257346 (Address of principa |
|
| June 13, 2025 |
NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 21, 2025 Exhibit 99.1 NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 21, 2025 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Annual and Extraordinary General Meeting (the “Meeting”) of the shareholders of XTL Biopharmaceuticals Ltd. (the “Company”) will be held at the offices of the Company’s attorneys, Doron Tikotzky Kantor Gutman |
|
| April 30, 2025 |
Exhibit 12.1 CERTIFICATION I, Noam Band, certify that: 1. I have reviewed this annual report on Form 20-F of XTL Biopharmaceuticals Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not mislea |
|
| April 30, 2025 |
XTL BIOPHARMACEUTICALS LTD. Insider Trading Policy Exhibit 11.1 XTL BIOPHARMACEUTICALS LTD. Insider Trading Policy This Insider Trading Policy (the “Policy”) describes the standards of XTL Biopharmaceuticals Ltd. and its subsidiaries (the “Company”) on trading, and causing the trading of, the Company’s securities while in possession of material non-public information. This Policy is divided into two parts. 1. The first part prohibits trading in ce |
|
| April 30, 2025 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 USC. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of XTL Biopharmaceuticals Ltd. (the “Company”) on Form 20-F for the year ending December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Noam Band, Chief Executive Off |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 30, 2025 |
EXCLUSIVE SUBLICENSE AGREEMENT by and between XTL BIOPHARMACEUTICALS LTD. BIOSSIL INC. Exhibit 4.11 EXCLUSIVE SUBLICENSE AGREEMENT by and between XTL BIOPHARMACEUTICALS LTD. and BIOSSIL INC. Exclusive Sublicense Agreement EXCLUSIVE SUBLICENSE AGREEMENT This Exclusive Sublicense Agreement (this “Agreement”) is effective as of February 12, 2025 (the “Effective Date”), by and between XTL Biopharmaceuticals Ltd., an Israeli corporation (“XTL”) and Biossil Inc., a company incorporated un |
|
| April 30, 2025 |
Exhibit 4.9 CEO Employment Agreement This Service Agreement (the “Agreement”) is made and entered into as of April 2st, 2025 (the “Effective Date”), by and between XTL Biopharmaceuticals Ltd., Israeli public company, Registration No. 520039470 having its principal offices at 26 Ben-Gurion St., Ramat Gan, 5112001, Israel (the “Company”) Mr. Noam Band, ID no. ****, residing at ****, Israel (the “” o |
|
| April 30, 2025 |
Exhibit 12.2 CERTIFICATION I, Itay Weinstein, certify that: 1. I have reviewed this report on Form 20-F of XTL Biopharmaceuticals Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleadi |
|
| April 30, 2025 |
Exhibit 4.8 SERVICES AGREEMENT THIS SERVICES AGREEMENT (the “Agreement”) entered into on the day of July 2020 (the “Signing Date”), by and between XTL Biopharmaceuticals Ltd., an Israeli publicly traded company, with its principal offices at 5 Badner St., Ramat Gan, Israel (the “Company”) and Mr. Shlomo Shalev, I.D. number **** (hereinafter referred to as the “Consultant” and collectively with the |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 26 Ben-Gurion St. Ramat Gan, 5112001, Israel (Address of principal executiv |
|
| April 7, 2025 |
Exhibit 99.1 XTL Names Mr. Noam Band as its New Chief Executive Officer Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) - XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”) announced today the appointment of Noam Band as the Company’s new Chief Executive Officer. Shlomo Shalev will continue as the Chairman |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 26 Ben-Gurion St. Ramat Gan, 5112001, Israel (Address of principal executiv |
|
| February 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February, 2025 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner St. Ramat Gan 4365603, Israel (Address of principal executive |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December, 2024 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 26 Ben-Gurion St. Ramat Gan 5112001, Israel (Address of principal execu |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December, 2024 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 26 Ben-Gurion St. Ramat Gan 5112001, Israel (Address of principal execu |
|
| November 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November, 2024 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) Ramat Gan, 4365603, Israel (Address of principal executive offices) Ind |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November, 2024 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) Ramat Gan, 4365603, Israel (Address of principal executive offices) Ind |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October, 2024 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) Ramat Gan, 4365603, Israel (Address of principal executive offices) Indi |
|
| August 14, 2024 |
Exhibit 99.1 XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Completed a Private Placement of $1.5 Million RAMAT GAN, ISRAEL, Aug. 14, 2024 (GLOBE NEWSWIRE) - August 14, 2024, XTL Biopharmaceutical |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August, 2024 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) Ramat Gan, 4365603, Israel (Address of principal executive offices) Indic |
|
| July 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July, 2024 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 26 Ben-Gurion St. Ramat Gan, 5112001, Israel (Address of principal executiv |
|
| June 12, 2024 |
Exhibit 99.3 |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June, 2024 001-36000 (Commission File Number) XTL Biopharmaceuticals Ltd. (Exact name of Registrant as specified in its charter) 26 Ben-Gurion St. Ramat Gan, Israel, 5112001 (Address of princip |
|
| June 12, 2024 |
Exhibit 99.2 XTL Biopharmaceuticals Ltd. PROXY FOR THE ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 22, 2024 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Shlomo Shalev, Chief Executive Officer, attorney, agent and proxy of the undersigned, with full power of substitution to each of them, to represent and to vote on beha |
|
| June 12, 2024 |
NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 22, 2024 Exhibit 99.1 NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 22, 2024 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Annual and Extraordinary General Meeting (the “Annual Meeting”) of the shareholders of XTL Biopharmaceuticals Ltd. (the “Company”) will be held at the offices of the Company’s attorneys, Doron Tikotzky Kantor |
|
| June 5, 2024 |
Exhibit 99.1 SHARE PURCHASE AGREEMENT THIS SHARE PURCHASE AGREEMENT (this “Agreement”) made effective as of June 5, 2024 (the “Effective Date”), by and among the current shareholders of the Company listed in Exhibit A attached hereto (the “Current Shareholders”) of THE SOCIAL PROXY LTD., an Israeli company, Registration No. 516115086 (the “Company”), and XTL Biopharmaceuticals Ltd., an Israeli pub |
|
| June 5, 2024 |
Exhibit 99.2 XTL Entered Definitive Agreement to Acquire The Social Proxy expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a Private Placement RAMAT GAN, ISRAEL, June 05, 2024 (GLOBE NEWSWIRE) - XTL Biopharmaceuticals Ltd. (the “Company” or “XTL”) announced today |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June, 2024 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 26 Ben-Gurion St. Ramat Gan, 5112001, Israel (Address of principal executiv |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May, 2024 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 26 Ben-Gurion St. Ramat Gan 5112001, Israel (Address of principal executive |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 30, 2024 |
Exhibit 12.2 CERTIFICATION I, Itay Weinstein, certify that: 1. I have reviewed this report on Form 20-F of XTL Biopharmaceuticals Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleadi |
|
| April 30, 2024 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 USC. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of XTL Biopharmaceuticals Ltd. (the “Company”) on Form 20-F for the year ending December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Shlomo Shalev, Chief Executive |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April, 2024 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner St. Ramat Gan 4365603, Israel (Address of principal executive off |
|
| April 30, 2024 |
Exhibit 12.1 CERTIFICATION I, Shlomo Shalev, certify that: 1. I have reviewed this annual report on Form 20-F of XTL Biopharmaceuticals Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not mi |
|
| April 30, 2024 |
Exhibit 99.7 XTL Biopharmaceuticals Ltd. Executive Officer Clawback Policy Approved by the Compensation Committee of the Board of Directors on November 23, 2023 (the “Adoption Date”) I. Purpose This Executive Officer Clawback Policy describes the circumstances under which Covered Persons of XTL Biopharmaceuticals Ltd. and any of its direct or indirect subsidiaries (the “Company”) will be required |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April, 2024 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive of |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2024 001-36000 (Commission File Number) XTL Biopharmaceuticals Ltd. (Exact name of Registrant as specified in its charter) 5 Badner St. Ramat Gan, Israel, 4365603 (Address of principal ex |
|
| March 21, 2024 |
Exhibit 99.2 XTL Biopharmaceuticals Ltd. PROXY FOR THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 30, 2024 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Shlomo Shalev, Chief Executive Officer, attorneys, agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to vote on behalf of |
|
| March 21, 2024 |
NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 30, 2024 Exhibit 99.1 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 30, 2024 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Extraordinary General Meeting (the “Meeting”) of the shareholders of XTL Biopharmaceuticals Ltd. (the “Company”) will be held at the offices of the Company’s attorneys, Doron Tikotzky Kantor Gutman Nass & Amit Gross, at |
|
| March 21, 2024 |
Exhibit 99.3 |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2024 001-36000 (Commission File Number) XTL Biopharmaceuticals Ltd. (Exact name of Registrant as specified in its charter) 5 Badner St. Ramat Gan, Israel, 4365603 (Addr |
|
| March 21, 2024 |
Exhibit 99.2 XTL Biopharmaceuticals Ltd. PROXY FOR THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 30, 2024 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Shlomo Shalev, Chief Executive Officer, attorneys, agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to vote on behalf of |
|
| March 21, 2024 |
Exhibit 99.3 |
|
| March 21, 2024 |
NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 30, 2024 Exhibit 99.1 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 30, 2024 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Extraordinary General Meeting (the “Meeting”) of the shareholders of XTL Biopharmaceuticals Ltd. (the “Company”) will be held at the offices of the Company’s attorneys, Doron Tikotzky Kantor Gutman Nass & Amit Gross, at |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March, 2024 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive of |
|
| March 20, 2024 |
Exhibit 99.1 XTL To Aquire The Social Proxy expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a Private Placement RAMAT GAN, ISRAEL, March 20, 2024 (GLOBE NEWSWIRE) - XTL Biopharmaceuticals Ltd. (the “Company” or “XTL”) announced today that it has entered into a bi |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November, 2023 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 26 Ben Gurion St. Ramat Gan, 4365603, Israel (Address of principal exec |
|
| October 20, 2023 |
Exhibit 99.2 XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) - XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) (“XTL” or the “Company”), a clinical stage biopharmaceutical company whose main assets consists of an IP portfolio relating to hCDR1 for the treatment of systemic lu |
|
| October 20, 2023 |
XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Exhibit 99.1 XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) - XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) (“XTL” or the “Company”), a clinical stage biopharmaceutical company whose main assets consists of an IP portfolio relating to hCDR1 for the treatment of systemic lupus erythematosus, or |
|
| October 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October, 2023 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 26 Ben Gurion Street Ramat Gan, 4365603 (Address of principal executive |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August, 2023 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 26 Ben Gurion St. Ramat Gan, 4365603, Israel (Address of principal execut |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May, 2023 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive offi |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 22, 2023 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 USC. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of XTL Biopharmaceuticals Ltd. (the “Company”) on Form 20-F for the year ending December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Shlomo Shalev, Chief Executive |
|
| March 22, 2023 |
Exhibit 12.2 CERTIFICATION I, Itay Weinstein, certify that: 1. I have reviewed this report on Form 20-F of XTL Biopharmaceuticals Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleadi |
|
| March 22, 2023 |
Exhibit 12.1 CERTIFICATION I, Shlomo Shalev, certify that: 1. I have reviewed this annual report on Form 20-F of XTL Biopharmaceuticals Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not mi |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March, 2023 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner St. Ramat Gan 4365603, Israel (Address of principal executive off |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February, 2023 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive |
|
| February 1, 2023 |
Notice and Proxy Statement with respect to the Company’s Annual General Meeting of Shareholders Exhibit 99.1 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 23, 2023 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Annual General Meeting (the “Annual Meeting”) of the shareholders of XTL Biopharmaceuticals Ltd. (the “Company”) will be held at the offices of the Company’s attorneys, Doron Tikotzky Kantor Gutman Nass & Amit Gross, at 7 M |
|
| February 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of February, 2023 011-36000 (Commission File Number) XTL Biopharmaceuticals Ltd. (Exact name of Registrant as specified in its charter) 5 Badner St. Ramat Gan, Israel, 5218102 ( |
|
| February 1, 2023 |
Exhibit 99.3 |
|
| February 1, 2023 |
Exhibit 99.2 XTL Biopharmaceuticals Ltd. PROXY FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 23, 2023 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Shlomo Shalev, Chief Executive Officer, attorney, agent and proxy of the undersigned, with full power of substitution to each of them, to represent and to vote on behalf of the unde |
|
| January 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of January, 2023 011-36000 (Commission File Number) XTL Biopharmaceuticals Ltd. (Exact name of Registrant as specified in its charter) 5 Badner St. Ramat Gan, Israel, 5218102 (Address of principal |
|
| January 20, 2023 |
Exhibit 99.2 XTL Biopharmaceuticals Ltd. PROXY FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 23, 2023 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Shlomo Shalev, Chief Executive Officer, attorney, agent and proxy of the undersigned, with full power of substitution to each of them, to represent and to vote on behalf of the unde |
|
| January 20, 2023 |
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 23, 2023 Exhibit 99.1 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 23, 2023 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Annual General Meeting (the “Annual Meeting”) of the shareholders of XTL Biopharmaceuticals Ltd. (the “Company”) will be held at the offices of the Company’s attorneys, Doron Tikotzky Kantor Gutman Nass & Amit Gross, at 7 M |
|
| January 20, 2023 |
Exhibit 99.3 |
|
| November 29, 2022 |
6-K 1 ea169385-6kxtlbiopharma.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November, 2022 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Ba |
|
| August 24, 2022 |
Exhibit 99.1 XTL BIOPHARMACEUTICALS LTD. CONDENSED INTERIM UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2022 INDEX Page Condensed Interim Unaudited Consolidated Financial Statements - in U.S. dollars: Unaudited Condensed Consolidated Statements of Financial Position 2 Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss) 3 Unaudited Condensed Statements of Change |
|
| August 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August, 2022 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive o |
|
| June 1, 2022 |
6-K 1 ea160779-6kxtlbiophar.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June, 2022 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner S |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 30, 2022 |
Exhibit 12.1 CERTIFICATION I, Shlomo Shalev, certify that: 1. I have reviewed this annual report on Form 20-F of XTL Biopharmaceuticals Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not mi |
|
| March 30, 2022 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 USC. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of XTL Biopharmaceuticals Ltd. (the “Company”) on Form 20-F for the year ending December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Shlomo Shalev, Chief Executive |
|
| March 30, 2022 |
Exhibit 15.2 March 30, 2022 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by XTL Biopharmaceuticals Ltd pursuant to Item 16F(a) of Form 20-F (copy attached), which we understand will be filed with the Securities and Exchange Commission as part of the Annual Report on Form 20-F of XTL Biopharmaceuticals Ltd dated March 30, |
|
| March 30, 2022 |
Consent of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Ltd.* Exhibit 15.1 We hereby consent to the incorporation by reference in the Registration Statement on Form F-3 (No. 333-208817) of XTL Biopharmaceuticals Ltd. of our report dated May 18, 2021 relating to the financial statements, which appears in this Form 20-F. /s/ Kesselman & Kesselman Tel Aviv, Israel Kesselman & Kesselman March 30, 2022 Certified Public Accountants (Isr.) A member firm of Pricewat |
|
| March 30, 2022 |
Exhibit 12.2 CERTIFICATION I, Itay Weinstein, certify that: 1. I have reviewed this report on Form 20-F of XTL Biopharmaceuticals Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleadi |
|
| March 30, 2022 |
Consent of Somekh Chaikin, a member firm of KPMG International* Exhibit 15.3 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the registration statement (No. 333-208817) on Form F-3, of our report dated March 30, 2022, with respect to the consolidated financial statements of XTL Biopharmaceuticals Ltd. /s/Somekh Chaikin Somekh Chaikin Certified Public Accountants (Isr.) A member firm of KPMG International |
|
| January 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January, 2022 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive |
|
| January 19, 2022 |
6-K 1 ea154180-6kxtlbiopharma.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January, 2022 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner St. Ramat Gan, 43656 |
|
| December 16, 2021 |
6-K 1 ea152228-6kxtlbiopharma.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December, 2021 011-36000 (Commission File Number) XTL Biopharmaceuticals Ltd. (Exact name of Registrant as specified in its ch |
|
| December 16, 2021 |
Exhibit 99.3 |
|
| December 16, 2021 |
Exhibit 99.2 XTL Biopharmaceuticals Ltd. PROXY FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JANUARY 19, 2022 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Shlomo Shalev, Chief Executive Officer, attorney, agent and proxy of the undersigned, with full power of substitution to each of them, to represent and to vote on behalf of the under |
|
| December 16, 2021 |
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JANUARY 19, 2022 Exhibit 99.1 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JANUARY 19, 2022 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Annual General Meeting (the ?Annual Meeting?) of the shareholders of XTL Biopharmaceuticals Ltd. (the ?Company?) will be held at the offices of the Company?s attorneys, Doron Tikotzky Kantor Gutman Nass & Amit Gross, at 7 Me |
|
| November 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November, 2021 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive |
|
| August 24, 2021 |
XTL BIOPHARMACEUTICALS LTD. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2021 Exhibit 99.2 XTL BIOPHARMACEUTICALS LTD. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2021 INDEX Page Unaudited Condensed Consolidated Financial Statements - in U.S. dollars: Consolidated Statements of Financial Position 2 Consolidated Statements of Comprehensive Income 3 Statements of Changes in Equity 4 Consolidated Statements of Cash Flows 5-6 Notes to Consolid |
|
| August 24, 2021 |
U.S. dollars in thousands (except per share data) Exhibit 99.1 OPERATING AND FINANCIAL REVIEW AND PROSPECTS You should read the following discussion and analysis in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K. The tables below present selected financial data for the six months ended as of June 30, 2021 and 2020 and the fiscal year ended as of December 31, 2020. We have derived this selected finan |
|
| August 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August, 2021 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive o |
|
| June 9, 2021 |
2,015,000 American Depositary Shares Each Representing 100 Ordinary Shares Filed pursuant to Rule 424(b)(3) Registration No. 333-208817 PROSPECTUS 2,015,000 American Depositary Shares Each Representing 100 Ordinary Shares This prospectus relates to the offer for sale of up to 201,500,000 ordinary shares represented by 2,015,000 American Depositary Shares, or ADSs, which consists of (i) 136,500,000 ordinary shares represented by 1,365,000 ADSs issuable upon exercise of un |
|
| June 2, 2021 |
As filed with the Securities and Exchange Commission on June 2, 2021 POS AM 1 ea141785-posama1xtlbiophar.htm POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-1 As filed with the Securities and Exchange Commission on June 2, 2021 Registration No. 333-208817 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM F-1 ON FORM F-3 XTL Biopharmaceuticals Ltd. (Exact name of registrant as specified in its charter) Israel 283 |
|
| May 19, 2021 |
Exhibit 12.2 CERTIFICATION I, Itay Weinstein, certify that: 1. I have reviewed this report on Form 20-F/A of XTL Biopharmaceuticals Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not mislea |
|
| May 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May, 2021 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive offi |
|
| May 19, 2021 |
Exhibit 12.1 CERTIFICATION I, Shlomo Shalev, certify that: 1. I have reviewed this annual report on Form 20-F/A of XTL Biopharmaceuticals Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not |
|
| May 19, 2021 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 USC. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of XTL Biopharmaceuticals Ltd. (the “Company”) on Form 20-F/A for the year ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Shlomo Shalev, Chief Executi |
|
| May 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A (Amendment No. 1) (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) O |
|
| May 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May, 2021 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive offi |
|
| April 5, 2021 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April, 2021 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive of |
|
| March 29, 2021 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March, 2021 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive of |
|
| March 15, 2021 |
Exhibit 12.1 CERTIFICATION I, Shlomo Shalev, certify that: 1. I have reviewed this annual report on Form 20-F of XTL Biopharmaceuticals Ltd. (the ?Company?); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not mi |
|
| March 15, 2021 |
Description of Securities (11) Exhibit 2(d) DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Our ordinary shares have been trading on the Tel Aviv Stock Exchange, or TASE, since July 2005. |
|
| March 15, 2021 |
Exhibit 12.2 CERTIFICATION I, Itay Weinstein, certify that: 1. I have reviewed this report on Form 20-F of XTL Biopharmaceuticals Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleadi |
|
| March 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 15, 2021 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 USC. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of XTL Biopharmaceuticals Ltd. (the ?Company?) on Form 20-F for the year ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), the undersigned, Shlomo Shalev, Chief Executive |
|
| February 22, 2021 |
Exhibit 99.3 |
|
| February 22, 2021 |
NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MARCH 29, 2021 Exhibit 99.1 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MARCH 29, 2021 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Extraordinary General Meeting (the ?Meeting?) of the shareholders of XTL Biopharmaceuticals Ltd. (the ?Company?) will be held at the offices of the Company?s attorneys, Doron Tikotzky Kantor Gutman Nass & Amit Gross, at |
|
| February 22, 2021 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of February 2021 001-36000 (Commission File Number) XTL Biopharmaceuticals Ltd. (Exact name of Registrant as specified in its charter) 5 Badner St. Ramat Gan, Israel, 4365603 (Address of principal |
|
| February 22, 2021 |
Exhibit 99.2 XTL Biopharmaceuticals Ltd. PROXY FOR THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MARCH 29, 2021 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Shlomo Shalev, Chief Executive Officer, attorneys, agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to vote on behalf of |
|
| January 7, 2021 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January, 2021 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive |
|
| December 31, 2020 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December, 2020 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive |
|
| November 25, 2020 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2020 011-36000 (Commission File Number) XTL Biopharmaceuticals Ltd. (Exact name of Registrant as specified in its charter) 5 Badner St. Ramat Gan, Israel, 5218102 (Address of principal |
|
| November 25, 2020 |
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 31, 2020 Exhibit 99.1 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 31, 2020 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Annual General Meeting (the “Annual Meeting”) of the shareholders of XTL Biopharmaceuticals Ltd. (the “Company”) will be held at the offices of the Company's attorneys, Doron Tikotzky Kantor Gutman Nass & Amit Gross, at 7 M |
|
| November 25, 2020 |
Annual General Meeting of Shareholders of XTL Biopharmaceuticals Ltd. Exhibit 99.3 Annual General Meeting of Shareholders of XTL Biopharmaceuticals Ltd. Date: December 31, 2020 See Voting Instruction On Reverse Side. Please make your marks like this: ☒ Use pen only For Against Abstain Annual General Meeting of Shareholders: 1. To approve the re-appointment of Kesselman & Kesselman, Israel CPAs, a member firm of PricewaterhouseCoopers International Limited, as the Co |
|
| November 25, 2020 |
Exhibit 99.2 XTL Biopharmaceuticals Ltd. PROXY FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 31, 2020 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Shlomo Shalev, Chief Executive Officer, attorney, agent and proxy of the undersigned, with full power of substitution to each of them, to represent and to vote on behalf of the unde |
|
| November 12, 2020 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November, 2020 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive |
|
| August 24, 2020 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August, 2020 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive o |
|
| July 7, 2020 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July, 2020 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive off |
|
| June 30, 2020 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June, 2020 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive off |
|
| May 27, 2020 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May, 2020 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive offi |
|
| May 26, 2020 |
Exhibit 99.3 |
|
| May 26, 2020 |
NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 30, 2020 Exhibit 99.1 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 30, 2020 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Extraordinary General Meeting (the “Meeting”) of the shareholders of XTL Biopharmaceuticals Ltd. (the “Company”) will be held at the offices of the Company’s attorneys, Doron Tikotzky Kantor Gutman Nass & Amit Gross, at |
|
| May 26, 2020 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May, 2020 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive offi |
|
| May 26, 2020 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2020 011-36000 (Commission File Number) XTL Biopharmaceuticals Ltd. (Exact name of Registrant as specified in its charter) 5 Badner St. Ramat Gan, Israel, 5218102 (Address of principal exec |
|
| May 26, 2020 |
Exhibit 99.2 XTL Biopharmaceuticals Ltd. PROXY FOR THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 30, 2020 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Mr. Shlomo Shalev, Chief Executive Officer, attorney, agent and proxy of the undersigned, with full power of substitution, to represent and to vote on behalf of the undersigned a |
|
| March 12, 2020 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 USC. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of XTL Biopharmaceuticals Ltd. (the “Company”) on Form 20-F for the year ending December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Doron Turgeman, Chief Executiv |
|
| March 12, 2020 |
XTLB / XTL Biopharmaceuticals Ltd. 20-F - - ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 12, 2020 |
Exhibit 12.1 CERTIFICATION I, Doron Turgeman, certify that: 1. I have reviewed this annual report on Form 20-F of XTL Biopharmaceuticals Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not m |
|
| March 12, 2020 |
Exhibit 12.2 CERTIFICATION I, Itay Weinstein, certify that: 1. I have reviewed this report on Form 20-F of XTL Biopharmaceuticals Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleadi |
|
| January 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January, 2020 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive |
|
| January 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January, 2020 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive |
|
| January 13, 2020 |
Notice and Proxy Statement with respect to the Company’s Annual General Meeting of Shareholders Exhibit 99.1 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JANUARY 22, 2020 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Annual General Meeting (the “Meeting”) of the shareholders of XTL Biopharmaceuticals Ltd. (the “Company”) will be held at the offices of the Company's attorneys, Doron Tikotzky Kantor Gutman Nass & Amit Gross, at 7 Metsada S |
|
| January 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2019 011-36000 (Commission File Number) XTL Biopharmaceuticals Ltd. (Exact name of Registrant as specified in its charter) 5 Badner St. Ramat Gan, Israel, 5218102 ( |
|
| December 18, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2019 011-36000 (Commission File Number) XTL Biopharmaceuticals Ltd. (Exact name of Registrant as specified in its charter) 5 Badner St. Ramat Gan, Israel, 5218102 (Address of principal |
|
| December 18, 2019 |
Annual General Meeting of Shareholders of XTL Biopharmaceuticals Ltd. Exhibit 99.3 Annual General Meeting of Shareholders of XTL Biopharmaceuticals Ltd. Date: January 22, 2020 See Voting Instruction On Reverse Side. Please make your marks like this: ☒ Use pen only Annual General Meeting of Shareholders: 1. To approve Kesselman & Kesselman, Israel CPAs, a member firm of PricewaterhouseCoopers International Limited, as the Company’s independent auditors for the fiscal |
|
| December 18, 2019 |
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JANUARY 22, 2020 Exhibit 99.1 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JANUARY 22, 2020 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Annual General Meeting (the “Meeting”) of the shareholders of XTL Biopharmaceuticals Ltd. (the “Company”) will be held at the offices of the Company's attorneys, Doron Tikotzky Kantor Gutman Nass & Amit Gross, at 7 Metsada S |
|
| December 18, 2019 |
Exhibit 99.2 XTL Biopharmaceuticals Ltd. PROXY FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JANUARY 22, 2020 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Josh Levine, Chief Executive Officer, attorney, agent and proxy of the undersigned, with full power of substitution, to represent and to vote on behalf of the undersigned all the ord |
|
| November 27, 2019 |
XTLB / XTL Biopharmaceuticals Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November, 2019 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive |
|
| October 31, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October, 2019 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive |
|
| September 4, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September, 2019 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executiv |
|
| May 30, 2019 |
6-K 1 f6k053019xtlbiopharma.htm CURRENT REPORT OF FOREIGN ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May, 2019 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner St |
|
| March 11, 2019 |
Exhibit 12.1 CERTIFICATION I, Josh Levine, certify that: 1. I have reviewed this annual report on Form 20-F of XTL Biopharmaceuticals Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misl |
|
| March 11, 2019 |
Exhibit 12.2 CERTIFICATION I, Itay Weinstein, certify that: 1. I have reviewed this report on Form 20-F of XTL Biopharmaceuticals Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleadi |
|
| March 11, 2019 |
XTLB / XTL Biopharmaceuticals Ltd. ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITIONAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES E |
|
| March 11, 2019 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 USC. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of XTL Biopharmaceuticals Ltd. (the “Company”) on Form 20-F for the year ending December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Josh Levine, Chief Executive O |
|
| December 27, 2018 |
6-K 1 f6k122718xtlbiopharm.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December, 2018 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badne |
|
| December 20, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December, 2018 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive |
|
| November 15, 2018 |
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 20, 2018 Exhibit 99.1 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 20, 2018 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Annual General Meeting (the “Meeting”) of the shareholders of XTL Biopharmaceuticals Ltd. (the “Company”) will be held at the offices of the Company's attorneys, Doron Tikotzky Kantor Gutman & Amit Gross, at 7 Metsada St., |
|
| November 15, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2018 011-36000 (Commission File Number) XTL Biopharmaceuticals Ltd. (Exact name of Registrant as specified in its charter) 5 Badner St. Ramat Gan, Israel, 5218102 (Address of principal |
|
| November 15, 2018 |
Exhibit 99.2 XTL Biopharmaceuticals Ltd. PROXY FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 20, 2018 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Josh Levine, Chief Executive Officer, attorney, agent and proxy of the undersigned, with full power of substitution, to represent and to vote on behalf of the undersigned all the or |
|
| November 15, 2018 |
Exhibit 99.3 |
|
| November 8, 2018 |
www. xtlbio. com XTL Biopharmaceuticals ( NASDAQ: XTLB) ( TASE: XTLB. TA) November 2018 Exhibit 99.1 www. xtlbio. com XTL Biopharmaceuticals ( NASDAQ: XTLB) ( TASE: XTLB. TA) November 2018 Forward Looking Statements Certain statements in this presentation are forward - looking within the meaning of the Private Securities Litigation Reform Act of 1995 . These statements may be identified by the use of forward - looking words such as "anticipate," "planned," "believe," "forecast," "e |
|
| November 8, 2018 |
6-K 1 f6k110818xtlbiopharma.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November, 2018 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badn |
|
| November 1, 2018 |
6-K 1 f6k110118xtlbiopharma.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November, 2018 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badn |
|
| July 24, 2018 |
6-K 1 f6k072418xtlbiopharma.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July, 2018 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner S |
|
| May 29, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May, 2018 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive offi |
|
| May 22, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May, 2018 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner St. Ramat Gan, 4365603, Israel (Address of principal executive offi |
|
| May 15, 2018 |
6-K 1 f6k051518xtlbiopharmac.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May, 2018 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Badner S |
|
| April 10, 2018 |
6-K 1 f6k041018xtlbiopharma.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2018 011-36000 (Commission File Number) XTL Biopharmaceuticals Ltd. (Exact name of Registrant as specified in its charter) |
|
| April 10, 2018 |
Exhibit 99.2 XTL Biopharmaceuticals Ltd. PROXY FOR THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 15, 2018 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Josh Levine, Chief Executive Officer, attorneys, agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to vote on behalf of the |
|
| April 10, 2018 |
NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 15, 2018 EX-99.1 2 f6k041018ex99-1xtlbio.htm NOTICE AND PROXY STATEMENT WITH RESPECT TO THE COMPANY'S EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Exhibit 99.1 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 15, 2018 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Extraordinary General Meeting (the “Meeting”) of the shareholders of XTL Biopharma |
|
| April 10, 2018 |
Exhibit 99.3 |
|
| March 15, 2018 |
Consent of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Ltd * Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-148085, No. 333-148754 and No. 333-154795) of XTL Biopharmaceuticals Ltd. of our report dated March 14, 2018 relating to the financial statements, which appears in this Form 20-F. Tel Aviv, Israel /s/ Kesselman & Kesselman Mar |
|
| March 15, 2018 |
Exhibit 12.1 CERTIFICATION I, Josh Levine, certify that: 1. I have reviewed this annual report on Form 20-F of XTL Biopharmaceuticals Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misl |
|
| March 15, 2018 |
Exhibit 12.2 CERTIFICATION I, Itay Weinstein, certify that: 1. I have reviewed this report on Form 20-F of XTL Biopharmaceuticals Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleadi |
|
| March 15, 2018 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 USC. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of XTL Biopharmaceuticals Ltd. (the “Company”) on Form 20-F for the year ending December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Josh Levine, Chief Executive O |
|
| March 15, 2018 |
XTLB / XTL Biopharmaceuticals Ltd. ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITIONAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES E |
|
| March 7, 2018 |
3,850,000 American Depositary Shares Each Representing 100 Ordinary Shares File Pursuant to Rule 424(b)(3) Registration No. 333- 208817 3,850,000 American Depositary Shares Each Representing 100 Ordinary Shares This prospectus relates to the offer for sale of up to 385,000,000 ordinary shares represented by 3,850,000 American Depositary Shares, or ADSs, which consists of (i) 140,000,000 ordinary shares represented by 1,400,000 unregistered ADSs originally issued to inves |
|
| March 2, 2018 |
XTLB / XTL Biopharmaceuticals Ltd. CORRESP XTL Biopharmaceuticals Ltd. 5 Badner St. Ramat Gan, Israel, 5218102 March 2, 2018 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey Gabor Re: XTL Biopharmaceuticals Ltd. Registration Statement on Form F-1 File No. 333-208817 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act |
|
| February 28, 2018 |
XTLB / XTL Biopharmaceuticals Ltd. F-1/A As filed with the Securities and Exchange Commission on February 28, 2018. Registration No. 333-208817 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 3 to FORM F-1 XTL Biopharmaceuticals Ltd. (Exact name of registrant as specified in its charter) Israel 2834 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Indust |
|
| February 1, 2018 |
As filed with the Securities and Exchange Commission on February 1, 2018. As filed with the Securities and Exchange Commission on February 1, 2018. Registration No. 333-208817 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 to FORM F-1 XTL Biopharmaceuticals Ltd. (Exact name of registrant as specified in its charter) Israel 2834 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industr |
|
| February 1, 2018 |
Exhibit 10.12 AMENDMED AND RESTATED EMPLOYMENT AGREEMENT This amended and restated employment agreement (the ?Agreement?) dated as of August 3, 2017 (the ?Signing Date?), by and between XTL Biopharmaceuticals Ltd., an Israeli company with its principal offices in 5 Ha'haroshet St., Ra'anana 43656, Israel, (the ?Company?), and Joshua Levine, I.D. Number: 321903650, an individual whose address is 25 |
|
| December 6, 2017 |
XTLB / XTL Biopharmaceuticals Ltd. 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December, 2017 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 HaCharoshet St., Raanana, 4365603, Israel (Address of principal execu |
|
| November 27, 2017 |
XTLB / XTL Biopharmaceuticals Ltd. 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November, 2017 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 HaCharoshet St., Raanana, 4365603, Israel (Address of principal execu |
|
| October 23, 2017 |
XTL Biopharmaceuticals 6-K (Current Report of Foreign Issuer) 6-K 1 tv4774926k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October, 2017 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 HaCharoshet St., Raanana, 4365603, Israel (Ad |
|
| September 26, 2017 |
XTL Biopharmaceuticals 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September, 2017 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 HaCharoshet St., Raanana, 4365603, Israel (Address of principal exec |
|
| September 12, 2017 |
XTL Biopharmaceuticals 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September, 2017 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 HaCharoshet St., Raanana, 4365603, Israel (Address of principal exec |
|
| August 3, 2017 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) 6-K 1 v4723146k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August, 2017 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 HaCharoshet St., Raanana, 4365603, Israel |
|
| July 27, 2017 |
XTL Biopharmaceuticals 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July, 2017 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 HaCharoshet St., Raanana, 4365603, Israel (Address of principal executive |
|
| June 22, 2017 |
NOTICE OF 2017 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 27, 2017 EX-99.1 2 v469060ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 NOTICE OF 2017 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 27, 2017 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Annual General Meeting (the “Meeting”) of the shareholders of XTL Biopharmaceuticals Ltd. (the “Company”) will be held at the offices of the Company's attorneys, Doron Tikotzky Kant |
|
| June 22, 2017 |
Exhibit 99.2 XTL Biopharmaceuticals Ltd. PROXY FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 27, 2017 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Josh Levine, Chief Executive Officer, attorneys, agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to vote on behalf of the unders |
|
| June 22, 2017 |
EX-99.3 4 v469060ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 |
|
| June 22, 2017 |
XTL Biopharmaceuticals 6-K (Current Report of Foreign Issuer) 6-K 1 v4690606k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2017 001-36000 (Commission File Number) XTL Biopharmaceuticals Ltd. (Exact name of Registrant as specified in its charter) 5 HaCharoshet St., Raanana, 4365603, Isra |
|
| June 15, 2017 |
XTL Biopharmaceuticals 6-K (Current Report of Foreign Issuer) 6-K 1 v4690556k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2017 001-36000 (Commission File Number) XTL Biopharmaceuticals Ltd. (Exact name of Registrant as specified in its charter) 5 HaCharoshet St., Raanana, 4365603, Isra |
|
| April 27, 2017 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April, 2017 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 HaCharoshet St., Raanana, 4365603, Israel (Address of principal executiv |
|
| April 5, 2017 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April, 2017 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 HaCharoshet St., Raanana, 4365603, Israel (Address of principal executiv |
|
| April 4, 2017 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April, 2017 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 HaCharoshet St., Raanana, 4365603, Israel (Address of principal executiv |
|
| April 3, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A Amendment No. 1 20-F/A 1 v46319820fa.htm 20-F/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A Amendment No. 1 (Mark One) ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ¨ TRANSITIONAL REPORT P |
|
| March 30, 2017 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March, 2017 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 Hacharoshet St. PO Box 4423 Raanana 4365603, Israel (Address of principa |
|
| March 30, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F 20-F 1 v46302220f.htm FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ¨ TRANSITIONAL REPORT PURSUANT TO SECTION |
|
| March 22, 2017 |
XTL Biopharmaceuticals 6-K (Current Report of Foreign Issuer) 6-K 1 v4623986k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March, 2017 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 Hacharoshet St. PO Box 4423 Raanana 4365603, Isr |
|
| March 9, 2017 |
Form of Warrant issued March 10, 2017 (8) Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| March 9, 2017 |
From of Securities Purchase Agreement dated March 7, 2017 (8) Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March , 2017, between XTL Biopharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to |
|
| March 9, 2017 |
XTL Biopharmaceuticals 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March, 2017 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 Hacharoshet St. PO Box 4423 Raanana 4365603, Israel (Address of principa |
|
| March 7, 2017 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March, 2017 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 HaCharoshet St., Raanana, 4365603, Israel (Address of principal executiv |
|
| March 1, 2017 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March, 2017 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 HaCharoshet St., Raanana, 4365603, Israel (Address of principal executiv |
|
| February 27, 2017 |
XTLB / XTL Biopharmaceuticals Ltd. / INTRACOASTAL CAPITAL, LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* XTL Biopharmaceuticals Ltd. (Name of Issuer) Ordinary Shares, NIS 0.1 par value per share** (Title of Class of Securities) 98386D307 (CUSIP Number) February 17, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 22, 2017 |
Form of Warrant issued February 17, 2017 (7) Exhibit 10.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| February 22, 2017 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February, 2017 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 Hacharoshet St. PO Box 4423 Raanana 4365603, Israel (Address of princ |
|
| February 22, 2017 |
Form of Securities Purchase Agreement dated February 17, 2017 (7) EX-10.3 5 v460062ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 16, 2017, between XTL Biopharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collec |
|
| February 22, 2017 |
Exhibit 10.2 February 16, 2017 STRICTLY CONFIDENTIAL XTL Biopharmaceuticals Ltd. 5 Hacharoshet Street Raanana, Israel Attn: Joshua Levine Dear Mr. Levine: Reference is made to the engagement agreement (the ?Engagement Agreement?), dated November 7, 2016, by and between XTL Biopharmaceuticals Ltd. (the ?Company?) and Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC (?Rodman?) pursuant to whic |
|
| February 22, 2017 |
EX-10.1 3 v460062ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 November 7, 2016 STRICTLY CONFIDENTIAL XTL Biopharmaceuticals Ltd. 5 Hacharoshet Street Raanana, Israel Attn: Joshua Levine Dear Mr. Levine: This letter agreement (this “Agreement”) constitutes the agreement between XTL Biopharmaceuticals Ltd. (the “Company”) and Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC (“Rodman”) that Rodman shal |
|
| February 22, 2017 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-194338 Prospectus Supplement (to Prospectus dated April 4, 2014) XTL Biopharmaceuticals Ltd. 100,000,000 Ordinary Shares Represented by 1,000,000 American Depositary Shares We are offering 100,000,000 ordinary shares represented by 1,000,000 American Depositary Shares, or ADSs to selected institutional and accredited investors under a securitie |
|
| February 17, 2017 |
XTL BIOPHARMACEUTICALS ANNOUNCES $2.5 MILLION REGISTERED DIRECT OFFERING Exhibit 99.1 XTL BIOPHARMACEUTICALS ANNOUNCES $2.5 MILLION REGISTERED DIRECT OFFERING Raanana, Israel, February 17, 2017 ? XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE:XTLB.TA) (?XTL? or the ?Company?), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced that it has entered into definitive agreements with institutional investors to receive |
|
| February 17, 2017 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February, 2017 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 HaCharoshet St., Raanana, 4365603, Israel (Address of principal execu |
|
| January 25, 2017 |
XTL Biopharmaceuticals 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January, 2017 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 HaCharoshet St., Raanana, 4365603, Israel (Address of principal execut |
|
| January 5, 2017 |
www.xtlbio.com XTL Biopharmaceuticals (NASDAQ: XTLB) (TASE: XTLB.TA) January 2017 Exhibit 99.1 www.xtlbio.com XTL Biopharmaceuticals (NASDAQ: XTLB) (TASE: XTLB.TA) January 2017 Forward Looking Statements Certain statements in this presentation are forward - looking within the meaning of the Private Securities Litigation Reform Act of 1995 . These statements may be identified by the use of forward - looking words such as "anticipate," "planned," "believe," "forecast," "estimat |
|
| January 5, 2017 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January, 2017 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 HaCharoshet St., Raanana, 4365603, Israel (Address of principal execut |
|
| January 5, 2017 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January, 2017 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 HaCharoshet St., Raanana, 4365603, Israel (Address of principal execut |
|
| December 6, 2016 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December, 2016 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 HaCharoshet St., Raanana, 4365603, Israel (Address of principal execu |
|
| November 14, 2016 |
XTL Biopharmaceuticals 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November, 2016 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 HaCharoshet St., Raanana, 4365603, Israel (Address of principal execu |
|
| November 8, 2016 |
PROTEOLOGICS LTD. INTERIM FINANCIAL INFORMATION AS OF SEPTEMBER 30, 2013 Exhibit 10.12 PROTEOLOGICS LTD. INTERIM FINANCIAL INFORMATION AS OF SEPTEMBER 30, 2013 UNAUDITED INDEX Page Statement of Financial Position 2 Statements of Operations 3 Statements of Changes in Equity 4 Statements of Cash Flows 5 - 6 Notes to Condensed Financial Statements 7 - 10 - - - - - - - - - - - - 1 - PROTEOLOGICS LTD. CONDENSED STATEMENT OF FINANCIAL POSITION September 30, December 31, 2013 |
|
| November 8, 2016 |
As filed with the Securities and Exchange Commission on November 7, 2016. F-1/A 1 v452377f1a.htm F-1/A As filed with the Securities and Exchange Commission on November 7, 2016. Registration No. 333-208817 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM F-1 XTL Biopharmaceuticals Ltd. (Exact name of registrant as specified in its charter) Israel 2834 Not Applicable (State or other jurisdiction of incorporation or organizati |
|
| November 7, 2016 |
XTLB / XTL Biopharmaceuticals Ltd. CORRESP - - CORRESP 1 filename1.htm XTL Biopharmaceuticals Ltd. 5 HaCharoshet St., Raanana, 4365603, Israel November 7, 2016 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attn: Alla Berenshteyn, Joseph McCann, Mary Beth Breslin and Suzanne Hayes Re: XTL Biopharmaceuticals Ltd. Registration Statement on Form F-1 Filed December 3 |
|
| September 27, 2016 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September, 2016 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 HaCharoshet St., Raanana, 4365603, Israel (Address of principal exec |
|
| September 27, 2016 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.1 OPERATING AND FINANCIAL REVIEW AND PROSPECTS You should read the following discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K, as well as in our Annual Report on Form 20-F filed on March 31, 2016. Unless the context requires otherwise, references in this report to ?XTL,? th |
|
| September 27, 2016 |
XTL BIOPHARMACEUTICALS LTD. INTERIM FINANCIAL INFORMATION AS OF JUNE 30, 2016 EX-99.2 3 v449494ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 XTL BIOPHARMACEUTICALS LTD. INTERIM FINANCIAL INFORMATION AS OF JUNE 30, 2016 UNAUDITED INDEX Page Condensed Consolidated Financial Statements - in U.S. dollars: Condensed Consolidated Statements of Financial Position 2 - 3 Condensed Consolidated Statements of Comprehensive Loss 4 Condensed Consolidated Statements of Changes in Equity 5 - 9 Con |
|
| September 27, 2016 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September, 2016 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 HaCharoshet St., Raanana, 4365603, Israel (Address of principal exec |
|
| September 7, 2016 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September, 2016 Commission File Number: 000-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 HaCharoshet St., Raanana, 4365603, Israel (Address of principal exec |
|
| August 11, 2016 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August, 2016 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 HaCharoshet St., Raanana, 4365603, Israel (Address of principal executi |
|
| June 1, 2016 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) 6-K 1 v4414456k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June, 2016 Commission File Number: 001-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 HaCharoshet St., Raanana, 4365603, Israel (A |
|
| March 31, 2016 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March, 2016 Commission File Number: 000-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 HaCharoshet St., Raanana 4365603 Israel (Address of principal executive |
|
| March 31, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F 20-F 1 v43560020f.htm 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR ¨ TRANSITIONAL REPORT PURSUANT TO SECTION 13 O |
|
| March 24, 2016 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) 6-K 1 v4352076k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March, 2016 Commission File Number: 000-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 HaCharoshet St., Raanana 4365603 Israel (Ad |
|
| March 21, 2016 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March, 2016 Commission File Number: 000-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 HaCharoshet St., Raanana 4365603 Israel (Address of principal executive |
|
| March 9, 2016 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March, 2016 Commission File Number: 000-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 HaCharoshet St., Raanana 4365603 Israel (Address of principal executive |
|
| March 2, 2016 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) 6-K 1 v4322256k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March, 2016 Commission File Number: 000-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 HaCharoshet St., Raanana 4365603 Israel (Ad |
|
| February 22, 2016 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) 6-K 1 v4323996k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February, 2016 Commission File Number: 000-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 HaCharoshet St., Raanana 4365603 Israel |
|
| February 18, 2016 |
EX-99.1 2 v432180ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Proxy Card – Part One In accordance with Regulation 7 of the Israeli Companies Regulations (written voting and position statements), 2005 (the "Regulations"). Company Name XTL Biopharmaceuticals Ltd. (the “Company”) Type of meeting An Annual General Meeting of Company Shareholders ("Meeting") Time and place of meeting: At the offices of the Com |
|
| February 18, 2016 |
Exhibit 99.2 |
|
| February 18, 2016 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February, 2016 Commission File Number: 000-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 HaCharoshet St., Raanana 4365603 Israel (Address of principal executi |
|
| February 10, 2016 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) 6-K 1 v4311816k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February, 2016 Commission File Number: 000-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 HaCharoshet St., Raanana 4365603 Israel |
|
| January 27, 2016 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January, 2016 Commission File Number: 000-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 HaCharoshet St., Raanana 4365603 Israel (Address of principal executiv |
|
| January 25, 2016 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) 6-K 1 v4295626k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January, 2016 Commission File Number: 000-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 HaCharoshet St., Raanana 4365603 Israel ( |
|
| January 13, 2016 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January, 2016 Commission File Number: 000-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 HaCharoshet St., Raanana 4365603 Israel (Address of principal executiv |
|
| January 11, 2016 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January, 2016 Commission File Number: 000-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 HaCharoshet St., Raanana 4365603 Israel (Address of principal executiv |
|
| December 31, 2015 |
EX-10.9 4 v427869ex10-9.htm EXHIBIT 10.9 Exhibit 10.9 EMPLOYMENT AGREEMENT This employment agreement (the “Agreement”) dated as of September 11, 2013 (the “Signing Date”), by and between XTL Biopharmaceuticals Ltd., an Israeli company with its principal offices in 85 Medinat Hayehudim St., Building G, Herzliya Business Park, Herzliya 4676670, Israel, (the "Company"), and Joshua Levine, I.D. Number |
|
| December 31, 2015 |
EX-10.11 6 v427869ex10-11.htm EXHIBIT 10.11 Exhibit 10.11 CONSULTING AGREEMENT THIS AGREEMENT (the “Agreement”) entered into on the 1 day of January 2015, by and between XTL Biopharmaceuticals Ltd., an Israeli publicly traded company, with its principal offices at Medinat Hayehudim St. 85, Herzliya, Israel (the "Company") and Schapiro Education Ltd., an Israeli corporation, number 515177111, of 28 |
|
| December 31, 2015 |
EX-21.1 7 v427869ex21-1.htm EXHIBIT 21.1 Exhibit 21.1 SUBSIDIARIES OF XTL BIOPHARMACEUTICALS LTD. Name of Subsidiary Percent Owned Jurisdiction of Incorporation XTEPO, Ltd. 100 % Israel |
|
| December 31, 2015 |
Exhibit 10.8 FIRST AMENDMENT TO THE LICENSE Agreement (?this Amendment?) Effective Date: September 6, 2015 Between YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED a company duly registered under the laws of Israel of P.O. Box 95, Rehovot 76100, Israel (hereinafter, ?Yeda?) and XTL Biopharmaceuticals Ltd. a company duly registered under the laws of Israel, having its principal place of business at 5 |
|
| December 31, 2015 |
2011 Share Option Plan dated August 29, 2011 (6) EX-10.3 2 v427869ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 XTL Biopharmaceuticals LTD. THE 2011 GLOBAL INCENTIVE OPTION SCHEME 1 XTL Biopharmaceuticals Ltd. – 2011 Global Incentive Option Scheme DEFINITIONS For purposes of the Global Incentive Option Scheme and related documents, including without limited, the Grant Notification Letter, the following definitions shall apply: (a) “Board” - the Board of |
|
| December 31, 2015 |
EX-10.10 5 v427869ex10-10.htm EXHIBIT 10.10 Exhibit 10.10 EMPLOYMENT AGREEMENT This employment agreement (the “Agreement”) dated as of January 9, 2014, effective as of January 5,2014 (the “Effective Date”), by and between XTL Biopharmaceuticals Ltd., an Israeli company with its principal offices in 85 Medinat Hayehudim, Herzliya, Israel, (the "Company"), and Mr. David Kestenbaum I.D. Number: 31438 |
|
| December 31, 2015 |
As filed with the Securities and Exchange Commission on December 31, 2015. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM F-1 XTL Biopharmaceuticals Ltd. (Exact name of registrant as specified in its charter) Israel 2834 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code |
|
| December 29, 2015 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December, 2015 Commission File Number: 000-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 HaCharoshet St., Raanana 4365603 Israel (Address of principal executi |
|
| December 1, 2015 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December, 2015 Commission File Number: 000-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant?s name into English) 5 HaCharoshet St., Raanana 4365603 Israel (Address of principal executi |
|
| October 13, 2015 |
XTL Biopharmaceuticals FORM 6-K (Current Report of Foreign Issuer) 6-K 1 v4220126-k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October, 2015 Commission File Number: 000-36000 XTL Biopharmaceuticals Ltd. (Translation of registrant’s name into English) 5 HaCharoshet St., Raanana 4365603 Israel |
